Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

Item
http://www.wikidata.org/entity/Q27853245
CIViC databaseRecent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical developmentCombination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinomaPhosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance.Antagonizing CD105 enhances radiation sensitivity in prostate cancer.[Preclinical models in head and neck tumors : Evaluation of cellular and molecular resistance mechanisms in the tumor microenvironment].Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
P2860

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

Item
http://www.wikidata.org/entity/Q27853245
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations.
@ast
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations.
@en
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations.
@nl
type
label
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations.
@ast
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations.
@en
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations.
@nl
altLabel
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations
@en
prefLabel
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations.
@ast
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations.
@en
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Taselisib (GDC-0032), a Potent ...... Activating PIK3CA Alterations
@en
P2093
P2860
P304
P31
P356
10.1158/1078-0432.CCR-15-2245
P407
P433
P478
P50
P577
P698
P932